• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4840639)   Today's Articles (10971)
For: Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2016;17:1521-32. [PMID: 27686946 DOI: 10.1016/S1470-2045(16)30313-8] [Citation(s) in RCA: 350] [Impact Index Per Article: 38.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2016] [Revised: 07/05/2016] [Accepted: 07/11/2016] [Indexed: 02/07/2023]
Number Cited by Other Article(s)
1
He D, Wei S, Geng F, Li L, Li F, Ge Y, Lv R, Li W, Hao Z, Jiang F, Meng C, Lu S, Zhang S. Prophylactic cerebral irradiation sensitizes relapsed sensitive small cell lung cancer to temozolomide: A retrospective cohort study. Oncol Lett 2025;30:327. [PMID: 40370642 PMCID: PMC12076553 DOI: 10.3892/ol.2025.15073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2024] [Accepted: 02/24/2025] [Indexed: 05/16/2025]  Open
2
Dharmaiah S, Malgulwar PB, Johnson WE, Chen BA, Sharin V, Whitfield BT, Alvarez C, Tadimeti V, Farooqi AS, Huse JT. G-quadruplex stabilizer CX-5461 effectively combines with radiotherapy to target α-thalassemia/mental retardation X-linked-deficient malignant glioma. Neuro Oncol 2025;27:932-947. [PMID: 39570009 PMCID: PMC12083236 DOI: 10.1093/neuonc/noae248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Indexed: 11/22/2024]  Open
3
Morfouace M, Bielle F, Razis E, Estrade F, Rubio A, Bautista F, de Rojas T, Vieito M, Meade S, Sanson M, Marques AC, Preusser M, Hatcher H, Balasubramanian GP, Pineda E, D'Hondt L, Duerinck J, Michotte A, Mawrin C, Ribalta T, Marucci G, Golfinopoulos V, Pfister SM, Jones DT, McCabe MG. Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations. Eur J Cancer 2025;223:115493. [PMID: 40393126 DOI: 10.1016/j.ejca.2025.115493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2024] [Revised: 04/22/2025] [Accepted: 05/04/2025] [Indexed: 05/22/2025]
4
Qiu Y, Li Y, Jiang C, Wu X, Liu W, Fan C, Ye X, He L, Xiao S, Zhao Q, Wu W, Chen K, Tan C, Li Y, Wang H, Liu F. Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial. Int J Radiat Oncol Biol Phys 2025;121:1168-1181. [PMID: 39615657 DOI: 10.1016/j.ijrobp.2024.11.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Revised: 11/12/2024] [Accepted: 11/15/2024] [Indexed: 12/22/2024]
5
Maddula M, McNamee N, Gan HK, Satgunaseelan L, Koh ES, Han CH, Thavaneswaran S. Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand. Curr Oncol 2025;32:183. [PMID: 40136387 PMCID: PMC11941661 DOI: 10.3390/curroncol32030183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2025] [Revised: 03/14/2025] [Accepted: 03/17/2025] [Indexed: 03/27/2025]  Open
6
Shi Z, Li KK, Kwan JS, Chung NY, Wong S, Chu AW, Chen H, Chan DT, Mao Y, Ng H. The molecular history of IDH-mutant astrocytomas without adjuvant treatment. Brain Pathol 2025;35:e13300. [PMID: 39473241 PMCID: PMC11835445 DOI: 10.1111/bpa.13300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Accepted: 08/05/2024] [Indexed: 02/20/2025]  Open
7
Roth P, Capper D, Calabrese E, Halasz LM, Jakola AS. Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma. Neurooncol Pract 2025;12:i29-i37. [PMID: 39776528 PMCID: PMC11703365 DOI: 10.1093/nop/npae100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2025]  Open
8
Himstead AS, Chen JW, Chu E, Perez-Rosendahl MA, Zheng M, Mathew S, Yuen CA. Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma. Biomedicines 2025;13:201. [PMID: 39857783 PMCID: PMC11762706 DOI: 10.3390/biomedicines13010201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2024] [Revised: 12/31/2024] [Accepted: 01/13/2025] [Indexed: 01/27/2025]  Open
9
Diaz M, Pan PC. Management of Low-Grade Gliomas. Cancer J 2025;31:e0760. [PMID: 39841424 PMCID: PMC11801446 DOI: 10.1097/ppo.0000000000000760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2025]
10
Fleming JL, Chakravarti A. Recent Advancements and Future Perspectives on Molecular Biomarkers in Adult Lower-Grade Gliomas. Cancer J 2025;31:e0758. [PMID: 39841423 DOI: 10.1097/ppo.0000000000000758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2025]
11
Ziu M, Halasz LM, Kumthekar PU, McGranahan TM, Lo SS, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update. J Neurooncol 2025;171:279-298. [PMID: 39565459 DOI: 10.1007/s11060-024-04861-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2024] [Accepted: 10/18/2024] [Indexed: 11/21/2024]
12
Darlix A, Bady P, Deverdun J, Lefort K, Rigau V, Le Bars E, Meriadec J, Carrière M, Coget A, Santarius T, Matys T, Duffau H, Hegi ME. Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment. Neurooncol Adv 2025;7:vdae224. [PMID: 40041202 PMCID: PMC11877643 DOI: 10.1093/noajnl/vdae224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2025]  Open
13
Cayuela N, Izquierdo C, Vaquero L, Càmara E, Bruna J, Simó M. Mapping glioma's impact on cognition: Insights from macrostructure, microstructure, and beyond. Neurooncol Adv 2025;7:vdaf003. [PMID: 39911704 PMCID: PMC11795312 DOI: 10.1093/noajnl/vdaf003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2025]  Open
14
Baumert BG, P M Jaspers J, Keil VC, Galldiks N, Izycka-Swieszewska E, Timmermann B, Grosu AL, Minniti G, Ricardi U, Dhermain F, Weber DC, van den Bent M, Rudà R, Niyazi M, Erridge S. ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma. Radiother Oncol 2025;202:110594. [PMID: 39454886 DOI: 10.1016/j.radonc.2024.110594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2024] [Accepted: 10/12/2024] [Indexed: 10/28/2024]
15
Gardner MM, Winter SF, Stahl F, Gerstner ER, Shih HA, Sherman J, Dietrich J, Parsons MW. Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas. J Neurooncol 2025;171:351-363. [PMID: 39400662 DOI: 10.1007/s11060-024-04850-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2024] [Accepted: 10/01/2024] [Indexed: 10/15/2024]
16
Kinslow CJ, Mehta MP. Future Directions in the Treatment of Low-Grade Gliomas. Cancer J 2025;31:e0759. [PMID: 39841425 DOI: 10.1097/ppo.0000000000000759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2025]
17
Wen K, Zhu W, Luo Z, Wang W. Machine learning-based identification of histone deacetylase-associated prognostic factors and prognostic modeling for low-grade glioma. Discov Oncol 2024;15:824. [PMID: 39714729 DOI: 10.1007/s12672-024-01713-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2024] [Accepted: 12/16/2024] [Indexed: 12/24/2024]  Open
18
Liang X, Li J, Lyu Y, Wang X. PIN4 could function as a prognostic biomarker for glioma. Asian J Surg 2024:S1015-9584(24)02609-5. [PMID: 39645496 DOI: 10.1016/j.asjsur.2024.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2024] [Accepted: 11/04/2024] [Indexed: 12/09/2024]  Open
19
Szivos L, Virga J, Mészár Z, Rostás M, Bakó A, Zahuczki G, Hortobágyi T, Klekner Á. Prognostic Role of Invasion-Related Extracellular Matrix Molecules in Diffusely Infiltrating Grade 2 and 3 Astrocytomas. Brain Sci 2024;14:1157. [PMID: 39595920 PMCID: PMC11592374 DOI: 10.3390/brainsci14111157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2024] [Revised: 11/12/2024] [Accepted: 11/14/2024] [Indexed: 11/28/2024]  Open
20
Hiong A, Lapidus AH, Gately L, Sinclair G, Ameratunga M. Herpes zoster in patients with glioma treated with temozolomide. J Clin Neurosci 2024;129:110816. [PMID: 39222582 DOI: 10.1016/j.jocn.2024.110816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2024] [Revised: 08/16/2024] [Accepted: 08/25/2024] [Indexed: 09/04/2024]
21
Ng S, Rigau V, Moritz-Gasser S, Gozé C, Darlix A, Herbet G, Duffau H. Long-term autonomy, professional activities, cognition, and overall survival after awake functional-based surgery in patients with IDH-mutant grade 2 gliomas: a retrospective cohort study. THE LANCET REGIONAL HEALTH. EUROPE 2024;46:101078. [PMID: 39381547 PMCID: PMC11458993 DOI: 10.1016/j.lanepe.2024.101078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/19/2024] [Revised: 09/04/2024] [Accepted: 09/09/2024] [Indexed: 10/10/2024]
22
Vaz-Salgado MÁ, García BC, Pérez IF, Munárriz BJ, Domarco PS, González AH, Villar MV, Caro RL, Delgado MLV, Sánchez JMS. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023). Clin Transl Oncol 2024;26:2856-2865. [PMID: 38662171 PMCID: PMC11467015 DOI: 10.1007/s12094-024-03456-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/08/2024] [Indexed: 04/26/2024]
23
Gately L, Drummond K, Dowling A, Bennett I, Freilich R, Phillips C, Ahern E, Campbell D, Dumas M, Campbell R, Harrup R, Kim GY, Reeves S, Collins IM, Gibbs P. Evolving Practice and Outcomes in Grade 2 Glioma: Real-World Data from a Multi-Institutional Registry. Cancers (Basel) 2024;16:3514. [PMID: 39456608 PMCID: PMC11506835 DOI: 10.3390/cancers16203514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2024] [Revised: 10/10/2024] [Accepted: 10/16/2024] [Indexed: 10/28/2024]  Open
24
Chen T, Meng J, Yu K, Huang T, Zhao J. Chromatin Licensing and DNA Replication Factor 1 (CDT1) Is a Potential Prognostic Biomarker Involved in the Malignant Biological Behavior of Glioma. ACS Pharmacol Transl Sci 2024;7:3131-3143. [PMID: 39416957 PMCID: PMC11475523 DOI: 10.1021/acsptsci.4c00312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2024] [Revised: 09/06/2024] [Accepted: 09/13/2024] [Indexed: 10/19/2024]
25
Kinslow CJ, Roy S, Iwamoto FM, Brown PD, DeStephano DM, Canoll PD, Qureshi SS, Gallito M, Sisti MB, Bruce JN, Horowitz DP, Kachnic LA, Neugut AI, Yu JB, Mehta MP, Cheng SK, Wang TJC. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro Oncol 2024;26:1839-1849. [PMID: 38943513 PMCID: PMC11449043 DOI: 10.1093/neuonc/noae102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Indexed: 07/01/2024]  Open
26
Li M, Liu J, Weng J, Dong G, Chen X, Cui Y, Ren X, Shen S, Jiang H, Zhang X, Zhao X, Li M, Wang X, Ren H, Li Q, Zhang Y, Cheng Q, Yu Y, Lin S. Unveiling hierarchy and spatial distribution of O6-methylguanine-DNA methyltransferase promoter methylation in World Health Organization grade 2-3 gliomas. Cancer Sci 2024;115:3403-3414. [PMID: 39101880 PMCID: PMC11447971 DOI: 10.1111/cas.16268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2024] [Revised: 06/13/2024] [Accepted: 06/24/2024] [Indexed: 08/06/2024]  Open
27
Albert NL, Le Rhun E, Minniti G, Mair MJ, Galldiks N, Tolboom N, Jakola AS, Niyazi M, Smits M, Verger A, Cicone F, Weller M, Preusser M. Translating the theranostic concept to neuro-oncology: disrupting barriers. Lancet Oncol 2024;25:e441-e451. [PMID: 39214115 DOI: 10.1016/s1470-2045(24)00145-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2024] [Revised: 02/23/2024] [Accepted: 03/08/2024] [Indexed: 09/04/2024]
28
Andrew Awuah W, Shah MH, Tan JK, Ranganathan S, Sanker V, Darko K, Tenkorang PO, Adageba BB, Ahluwalia A, Shet V, Aderinto N, Kundu M, Abdul‐Rahman T, Atallah O. Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches. CNS Neurosci Ther 2024;30:e70013. [PMID: 39215399 PMCID: PMC11364516 DOI: 10.1111/cns.70013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Revised: 07/23/2024] [Accepted: 08/12/2024] [Indexed: 09/04/2024]  Open
29
Zhu E, Wang J, Shi W, Chen Z, Zhu M, Xu Z, Li L, Shan D. Utilizing machine learning to tailor radiotherapy and chemoradiotherapy for low-grade glioma patients. PLoS One 2024;19:e0306711. [PMID: 39163387 PMCID: PMC11335161 DOI: 10.1371/journal.pone.0306711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 06/23/2024] [Indexed: 08/22/2024]  Open
30
Schiff D. Low-Grade Gliomas: A New Mutation, New Targeted Therapy, and Many Questions. Neurology 2024;103:e209688. [PMID: 39008801 DOI: 10.1212/wnl.0000000000209688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/17/2024]  Open
31
Budhiraja S, McManus G, Baisiwala S, Perrault EN, Cho S, Saathoff M, Chen L, Park CH, Kazi HA, Dmello C, Lin P, James CD, Sonabend AM, Heiland DH, Ahmed AU. ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma. Neuro Oncol 2024;26:1421-1437. [PMID: 38506351 PMCID: PMC11300013 DOI: 10.1093/neuonc/noae059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Indexed: 03/21/2024]  Open
32
Staicu GA, Tataranu LG, Tache DE, Popescu SO, Artene SA, Danoiu S, Sfredel V, Barcan EN, Baloi SC, Dricu A. Evaluation of Single and Combined Temozolomide and Doxorubicin Treatment Responses in Low- and High-Grade Glioma In Vitro. Cureus 2024;16:e66928. [PMID: 39280423 PMCID: PMC11401637 DOI: 10.7759/cureus.66928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/14/2024] [Indexed: 09/18/2024]  Open
33
Kotecha R, Schiff D, Chakravarti A, Fleming JL, Brown PD, Puduvalli VK, Vogelbaum MA, Gondi V, Gallus M, Okada H, Mehta MP. Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era. J Clin Oncol 2024;42:2588-2598. [PMID: 38833641 PMCID: PMC11283772 DOI: 10.1200/jco.23.02195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Revised: 03/04/2024] [Accepted: 04/04/2024] [Indexed: 06/06/2024]  Open
34
Tao Q, Yang S, Wang S, Yang Y, Yu S, Pan Y, Li Y, Zhang J, Hu C. Neural Progenitor Cell-Mediated Magnetic Nanoparticles for Magnetic Resonance Imaging and Photothermal Therapy of Glioma. ACS APPLIED BIO MATERIALS 2024;7:4553-4561. [PMID: 38875521 DOI: 10.1021/acsabm.4c00414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2024]
35
Rudà R, Horbinski C, van den Bent M, Preusser M, Soffietti R. IDH inhibition in gliomas: from preclinical models to clinical trials. Nat Rev Neurol 2024;20:395-407. [PMID: 38760442 DOI: 10.1038/s41582-024-00967-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/26/2024] [Indexed: 05/19/2024]
36
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F, Dehais C. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. Eur J Cancer 2024;202:114034. [PMID: 38537315 DOI: 10.1016/j.ejca.2024.114034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2024] [Accepted: 03/20/2024] [Indexed: 04/21/2024]
37
Wu G, Shi Z, Li Z, Xie X, Tang Q, Zhu J, Yang Z, Wang Y, Wu J, Yu J. Study of radiochemotherapy decision-making for young high-risk low-grade glioma patients using a macroscopic and microscopic combined radiomics model. Eur Radiol 2024;34:2861-2872. [PMID: 37889272 DOI: 10.1007/s00330-023-10378-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 09/06/2023] [Accepted: 09/16/2023] [Indexed: 10/28/2023]
38
Hu X, Zhao M, Bai M, Xue Z, Wang F, Zhu Z, Yu J, Yue J. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation. Cancer Lett 2024;586:216676. [PMID: 38278469 DOI: 10.1016/j.canlet.2024.216676] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 01/22/2024] [Accepted: 01/23/2024] [Indexed: 01/28/2024]
39
Nie J, Li Q, Yin H, Yang J, Li M, Li Q, Fan X, Zhao Q, Wen Z. NPS-2143 inhibit glioma progression by suppressing autophagy through mediating AKT-mTOR pathway. J Cell Mol Med 2024;28:e18221. [PMID: 38509759 PMCID: PMC10955153 DOI: 10.1111/jcmm.18221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 02/16/2024] [Accepted: 02/22/2024] [Indexed: 03/22/2024]  Open
40
Sasaki H, Kitamura Y, Toda M, Hirose Y, Yoshida K. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy. Brain Tumor Pathol 2024;41:43-49. [PMID: 38564040 DOI: 10.1007/s10014-024-00480-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 03/25/2024] [Indexed: 04/04/2024]
41
Wei J, Li Y, Zhou W, Ma X, Hao J, Wen T, Li B, Jin T, Hu M. The construction of a novel prognostic prediction model for glioma based on GWAS-identified prognostic-related risk loci. Open Med (Wars) 2024;19:20240895. [PMID: 38584840 PMCID: PMC10996933 DOI: 10.1515/med-2024-0895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 11/17/2023] [Accepted: 12/08/2023] [Indexed: 04/09/2024]  Open
42
Malta TM, Sabedot TS, Morosini NS, Datta I, Garofano L, Vallentgoed W, Varn FS, Aldape K, D'Angelo F, Bakas S, Barnholtz-Sloan JS, Gan HK, Hasanain M, Hau AC, Johnson KC, Cazacu S, deCarvalho AC, Khasraw M, Kocakavuk E, Kouwenhoven MC, Migliozzi S, Niclou SP, Niers JM, Ormond DR, Paek SH, Reifenberger G, Sillevis Smitt PA, Smits M, Stead LF, van den Bent MJ, Van Meir EG, Walenkamp A, Weiss T, Weller M, Westerman BA, Ylstra B, Wesseling P, Lasorella A, French PJ, Poisson LM, Verhaak RG, Iavarone A, Noushmehr H. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen. Cancer Res 2024;84:741-756. [PMID: 38117484 PMCID: PMC10911804 DOI: 10.1158/0008-5472.can-23-2093] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 09/15/2023] [Accepted: 12/13/2023] [Indexed: 12/21/2023]
43
Mohamed AA, Alshaibi R, Faragalla S, Mohamed Y, Lucke-Wold B. Updates on management of gliomas in the molecular age. World J Clin Oncol 2024;15:178-194. [PMID: 38455131 PMCID: PMC10915945 DOI: 10.5306/wjco.v15.i2.178] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 01/06/2024] [Accepted: 01/25/2024] [Indexed: 02/20/2024]  Open
44
Zheng S, Rammohan N, Sita T, Teo PT, Wu Y, Lesniak M, Sachdev S, Thomas TO. GlioPredictor: a deep learning model for identification of high-risk adult IDH-mutant glioma towards adjuvant treatment planning. Sci Rep 2024;14:2126. [PMID: 38267516 PMCID: PMC10808248 DOI: 10.1038/s41598-024-51765-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 01/09/2024] [Indexed: 01/26/2024]  Open
45
Chen J, Lu R, Peng Y, Lai Y, Cai Z, Zheng D, Xie A, Huang K, Liang C, Zhang H. MCU promotes the migration of glioma cells by activating p38 through TFEB-mediated autophagy. J Cancer 2024;15:1257-1270. [PMID: 38356708 PMCID: PMC10861810 DOI: 10.7150/jca.89485] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Accepted: 12/13/2023] [Indexed: 02/16/2024]  Open
46
Shikalov A, Koman I, Kogan NM. Targeted Glioma Therapy-Clinical Trials and Future Directions. Pharmaceutics 2024;16:100. [PMID: 38258110 PMCID: PMC10820492 DOI: 10.3390/pharmaceutics16010100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 01/05/2024] [Accepted: 01/08/2024] [Indexed: 01/24/2024]  Open
47
Weller M, Felsberg J, Hentschel B, Gramatzki D, Kubon N, Wolter M, Reusche M, Roth P, Krex D, Herrlinger U, Westphal M, Tonn JC, Regli L, Maurage CA, von Deimling A, Pietsch T, Le Rhun E, Reifenberger G. Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma. Acta Neuropathol 2024;147:11. [PMID: 38183430 PMCID: PMC10771615 DOI: 10.1007/s00401-023-02662-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Revised: 11/19/2023] [Accepted: 11/20/2023] [Indexed: 01/08/2024]
48
Williamson A, Houston P, Paterson J, Chalmers AJ, McLoone P, Fullerton N, Foo SY, James A, Nowicki S. Dosimetric comparison of hippocampal-sparing technologies in patients with low-grade glioma. Neurooncol Adv 2024;6:vdae131. [PMID: 39220244 PMCID: PMC11364934 DOI: 10.1093/noajnl/vdae131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/04/2024]  Open
49
Darlix A, Monnier M, Castan F, Coutant L, Fabbro M, Denis-Chammas È, Carrière M, Menjot-de-Champfleur N, Rigau V, Duffau H, Guerdoux E. Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: A feasibility study. Neurooncol Adv 2024;6:vdae084. [PMID: 38946878 PMCID: PMC11212068 DOI: 10.1093/noajnl/vdae084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/02/2024]  Open
50
Wu C, Li Y, Luo Y, Dai Y, Qin J, Liu N, Xu R, Li X, Zhang P. Analysis of glutathione Stransferase mu class 5 gene methylation as a prognostic indicator in low-grade gliomas. Technol Health Care 2024;32:3925-3942. [PMID: 39031395 PMCID: PMC11612950 DOI: 10.3233/thc-231316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Accepted: 05/22/2024] [Indexed: 07/22/2024]
PrevPage 1 of 8 1234578Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA